Wegovy Cost and Insurance Coverage

Wegovy List Price and Self-Pay Options

The list price for Wegovy (semaglutide 2.4 mg, injectable) is approximately $1,350 per month for a four-week supply 1Ref 1Novo Nordisk (2026).Wegovy Cost, Coverage, and Savings Resources.Wegovy list price ($1,350/month), NovoCare self-pay pricing ($199–$399/month injectable, $149/month oral), and savings card offer ($25/month for commercially insured patients). This represents the sticker price before insurance or manufacturer savings are applied — most patients do not pay this amount.

Novo Nordisk's NovoCare Pharmacy self-pay program offers a lower direct option: the injectable pen is available starting at $199 per month for lower doses (0.25 mg and 0.5 mg), rising to $349/month for the full dose range and $399/month for the high-dose 7.2 mg pen 1Ref 1Novo Nordisk (2026).Wegovy Cost, Coverage, and Savings Resources.Wegovy list price ($1,350/month), NovoCare self-pay pricing ($199–$399/month injectable, $149/month oral), and savings card offer ($25/month for commercially insured patients). A recently launched oral semaglutide tablet (Wegovy pill) is available starting at $149/month for the 1.5 mg dose through this same program.

These self-pay prices require enrolling through the NovoCare Pharmacy directly rather than using a retail pharmacy.

Savings Cards for Commercially Insured Patients

Patients with commercial (private) insurance — including employer-sponsored plans — may enroll in the Wegovy Savings Offer, which can reduce out-of-pocket costs to as little as $25 per month (maximum savings of $100 per month per fill) 1Ref 1Novo Nordisk (2026).Wegovy Cost, Coverage, and Savings Resources.Wegovy list price ($1,350/month), NovoCare self-pay pricing ($199–$399/month injectable, $149/month oral), and savings card offer ($25/month for commercially insured patients).

Key eligibility rules: - Must have commercial insurance that covers Wegovy (even partially) - Government beneficiaries — Medicare, Medicaid, and Tricare — are excluded from manufacturer savings cards by federal law - Enrollment is available at novocare.com or by texting SAVE to 83757

The savings card does not work as a substitute for insurance; it reduces the copay after insurance processes the claim.

Commercial Insurance: Prior Authorization Criteria

Most commercial plans that cover Wegovy require a prior authorization (PA) before filling the prescription. Approval is not automatic — the prescribing clinician must submit documentation, and 83% of people with Wegovy coverage still face PA or step-therapy requirements 2Ref 2Novo Nordisk / NovoCare prescriber resources (2026).Initiating Wegovy Prior Authorization.Prior authorization documentation requirements (BMI, comorbidities, prior therapies, ICD-10 codes); 83% of covered patients face PA or step-therapy restrictions.

Typical criteria insurers require: - BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related condition (type 2 diabetes, hypertension, obstructive sleep apnea, or cardiovascular disease) - Documentation of prior weight loss attempts through structured diet and/or exercise programs, often for 3–6 months - Some plans require step therapy — trying and failing a lower-cost anti-obesity medication (such as orlistat or phentermine) before approving Wegovy

PA timelines vary: most plans respond within 1–7 business days for standard requests. The most frequent denial reason is incomplete medical records 2Ref 2Novo Nordisk / NovoCare prescriber resources (2026).Initiating Wegovy Prior Authorization.Prior authorization documentation requirements (BMI, comorbidities, prior therapies, ICD-10 codes); 83% of covered patients face PA or step-therapy restrictions.

Coverage exclusions remain common. Many employer-sponsored plans have explicitly removed GLP-1 drugs for weight loss from their formularies, even when the same molecule (Ozempic, lower dose) is covered for type 2 diabetes 3Ref 3Cubanski J, Koma W, Damico A, Neuman T (2024).A New Use for Wegovy Opens the Door to Medicare Coverage for Millions of People with Obesity.Medicare Part D covers Wegovy only for cardiovascular risk reduction in patients with established CVD; approximately 3.6 million Medicare beneficiaries (7%) meet the qualifying criteria; Medicare is prohibited by law from covering Wegovy for weight loss alone.

Medicare Coverage: Cardiovascular Indication Only

Medicare Part D covers Wegovy for a specific, narrow indication: reducing the risk of cardiovascular death, heart attack, or stroke in adults with established cardiovascular disease who are overweight or obese 3Ref 3Cubanski J, Koma W, Damico A, Neuman T (2024).A New Use for Wegovy Opens the Door to Medicare Coverage for Millions of People with Obesity.Medicare Part D covers Wegovy only for cardiovascular risk reduction in patients with established CVD; approximately 3.6 million Medicare beneficiaries (7%) meet the qualifying criteria; Medicare is prohibited by law from covering Wegovy for weight loss alone. This coverage pathway opened following the SELECT trial, a randomized study of 17,604 adults without diabetes that showed semaglutide 2.4 mg reduced major cardiovascular events by 20% (hazard ratio 0.80; 95% CI 0.72–0.90) compared with placebo over approximately 40 months 4Ref 4Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (SELECT Investigators) (2023).Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.SELECT trial: semaglutide 2.4 mg reduced major cardiovascular events (CV death, non-fatal MI, non-fatal stroke) by 20% vs. placebo (HR 0.80; 95% CI 0.72–0.90; p<0.001) in 17,604 adults with CVD and obesity/overweight without diabetes, over approximately 40 months — the clinical basis for Medicare's cardiovascular coverage of Wegovy.

Medicare does not cover Wegovy for weight loss or weight management alone, even when medically indicated.

Who qualifies under Medicare: - Prior heart attack, stroke, or peripheral arterial disease — AND - Obesity (BMI ≥ 30) or overweight (BMI ≥ 27) - Approximately 3.6 million Medicare enrollees meet these criteria, representing 7% of all beneficiaries 3Ref 3Cubanski J, Koma W, Damico A, Neuman T (2024).A New Use for Wegovy Opens the Door to Medicare Coverage for Millions of People with Obesity.Medicare Part D covers Wegovy only for cardiovascular risk reduction in patients with established CVD; approximately 3.6 million Medicare beneficiaries (7%) meet the qualifying criteria; Medicare is prohibited by law from covering Wegovy for weight loss alone

For eligible patients, a Medicare Part D copay maximum of $50 per month applies as of mid-2026. Patients who do not have qualifying cardiovascular disease are not covered under current Medicare law, regardless of BMI.

Medicaid Coverage: Highly Variable by State

Medicaid coverage for Wegovy and other GLP-1 medications for obesity is state-by-state and rapidly changing. As of January 2026, only 13 state Medicaid programs cover GLP-1 drugs for obesity under fee-for-service 5Ref 5KFF (2026).Medicaid Coverage of and Spending on GLP-1s.As of January 2026, only 13 state Medicaid programs cover GLP-1 drugs for obesity under fee-for-service, down from 16 states in October 2025, with California, New Hampshire, Pennsylvania, and South Carolina among recent dropouts due to budget pressures — down from 16 states in late 2025. Several states including California and South Carolina removed coverage effective January 2026 due to budget pressures from rising drug costs.

When a state Medicaid program does cover Wegovy, utilization controls such as prior authorization typically apply.

To find the current status in a given state, the relevant resource is the state Medicaid program's preferred drug list (PDL), which is updated periodically and available through the state's Medicaid agency website.

What to Do If Insurance Denies Wegovy

An initial denial is not necessarily final. A meaningful share of coverage appeals succeed — in some analyses, over 44% of insurance denials are overturned on appeal 6Ref 6Medical News Today / Healthline Media (2024).How to Appeal a Wegovy Insurance Denial.Appeal process for Wegovy denial: internal appeal with letter of medical necessity, 6-month window to file, external independent review for ACA-compliant plans, approximately 44% of denied claims are overturned on appeal.

Steps after a denial:

1. Request the denial in writing. The insurer is required to provide an Explanation of Benefits stating the specific reason for denial. 2. Review the denial reason. Common reasons: not medically necessary, plan exclusion of weight-loss medications, or step-therapy not completed. 3. File a first-level internal appeal. This typically involves a letter of medical necessity from the prescribing clinician documenting BMI, weight-related comorbidities, and prior weight-loss attempts. Patients have up to 6 months from the denial notice to file in most cases. 4. Request an external review. If the internal appeal fails, patients covered by ACA-compliant plans (most plans issued after March 2010) can request an independent external review — a licensed clinician outside the insurer evaluates medical necessity. 5. Escalate to a state insurance commissioner if the external review is not offered or if the process is not followed correctly.

Patients who believe their plan excluded weight-loss drugs as a blanket policy — rather than based on individual clinical review — may have additional rights under state mental-health parity or anti-discrimination provisions 6Ref 6Medical News Today / Healthline Media (2024).How to Appeal a Wegovy Insurance Denial.Appeal process for Wegovy denial: internal appeal with letter of medical necessity, 6-month window to file, external independent review for ACA-compliant plans, approximately 44% of denied claims are overturned on appeal.

Patient Assistance and Low-Income Options

Novo Nordisk offers the NovoCare Patient Assistance Program for uninsured or underinsured patients who meet income criteria (generally below 400% of the federal poverty level — approximately $62,400/year for a single individual in 2026) 1Ref 1Novo Nordisk (2026).Wegovy Cost, Coverage, and Savings Resources.Wegovy list price ($1,350/month), NovoCare self-pay pricing ($199–$399/month injectable, $149/month oral), and savings card offer ($25/month for commercially insured patients). The program can provide Wegovy at no cost or reduced cost.

Two additional options to consider:

• NovoCare Pharmacy direct self-pay: Described above; available to anyone regardless of income at the published self-pay prices.
• Oral semaglutide (Wegovy pill): The FDA-approved oral formulation launched in 2026 at a starting self-pay price of $149/month for lower doses, which is lower than the injectable self-pay floor. Efficacy data at approved doses is lower than the injectable (the oral formulation is still undergoing dose-escalation studies for weight-loss-equivalent outcomes).

Compounded semaglutide from licensed compounding pharmacies was available during the FDA-declared shortage period but the FDA resolved the Wegovy shortage, which has substantially restricted access to compounded versions. Telehealth programs advertising "Wegovy-equivalent" medications at substantially lower prices than the brand should be reviewed carefully to confirm what active ingredient and source is being used.